MX2023004515A - Metodos para evaluar el riesgo de desarrollar una enfermedad. - Google Patents

Metodos para evaluar el riesgo de desarrollar una enfermedad.

Info

Publication number
MX2023004515A
MX2023004515A MX2023004515A MX2023004515A MX2023004515A MX 2023004515 A MX2023004515 A MX 2023004515A MX 2023004515 A MX2023004515 A MX 2023004515A MX 2023004515 A MX2023004515 A MX 2023004515A MX 2023004515 A MX2023004515 A MX 2023004515A
Authority
MX
Mexico
Prior art keywords
methods
disease
developing
risk
assessing risk
Prior art date
Application number
MX2023004515A
Other languages
English (en)
Inventor
Richard Allman
Kevin Wong
Nick Murphy
Gillian Dite
Aviv Gafni
Original Assignee
Genetic Tech Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020903793A external-priority patent/AU2020903793A0/en
Application filed by Genetic Tech Limited filed Critical Genetic Tech Limited
Publication of MX2023004515A publication Critical patent/MX2023004515A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Theoretical Computer Science (AREA)
  • Databases & Information Systems (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)

Abstract

La presente descripción se refiere a métodos y sistemas para evaluar el riesgo de que un sujeto humano desarrolle una enfermedad tal como enfermedad arterial coronaria, fibrilación auricular o diabetes Tipo 2. Estos métodos pueden combinarse con el riesgo clínico de los sujetos para mejorar el análisis de riesgo. Tales métodos pueden usarse para ayudar a la toma de decisiones sobre los regímenes terapéuticos y de monitoreo apropiados.
MX2023004515A 2020-10-20 2021-10-19 Metodos para evaluar el riesgo de desarrollar una enfermedad. MX2023004515A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2020903793A AU2020903793A0 (en) 2020-10-20 Methods of assessing risk of developing a disease
PCT/AU2021/051218 WO2022082261A1 (en) 2020-10-20 2021-10-19 Methods of assessing risk of developing a disease

Publications (1)

Publication Number Publication Date
MX2023004515A true MX2023004515A (es) 2023-05-04

Family

ID=81291031

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004515A MX2023004515A (es) 2020-10-20 2021-10-19 Metodos para evaluar el riesgo de desarrollar una enfermedad.

Country Status (10)

Country Link
US (1) US20230383349A1 (es)
EP (1) EP4232597A1 (es)
JP (1) JP2023546240A (es)
KR (1) KR20230092953A (es)
CN (1) CN116348615A (es)
AU (1) AU2021366960A1 (es)
CA (1) CA3192122A1 (es)
IL (1) IL301112A (es)
MX (1) MX2023004515A (es)
WO (1) WO2022082261A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024020441A1 (en) * 2022-07-21 2024-01-25 Pioneer Hi-Bred International, Inc. Artificial intelligence-guided marker assisted selection

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101582321B1 (ko) * 2006-12-05 2016-01-05 디코드 제네틱스 이에이치에프 심장성 부정맥의 위험 관리를 위한 유전적 마커
EP3093351B1 (en) * 2008-07-09 2018-04-18 Celera Corporation Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof
WO2011042920A1 (en) * 2009-10-07 2011-04-14 Decode Genetics Ehf Genetic variants indicative of vascular conditions
EP2554679B1 (en) * 2011-08-05 2016-03-02 Gendiag.exe, S.L. Genetic markers for cardiovascular disease risk assessment
US20190017119A1 (en) * 2017-07-12 2019-01-17 The General Hospital Corporation Genetic Risk Predictor

Also Published As

Publication number Publication date
KR20230092953A (ko) 2023-06-26
IL301112A (en) 2023-05-01
AU2021366960A1 (en) 2023-04-20
US20230383349A1 (en) 2023-11-30
CN116348615A (zh) 2023-06-27
JP2023546240A (ja) 2023-11-01
EP4232597A1 (en) 2023-08-30
WO2022082261A1 (en) 2022-04-28
CA3192122A1 (en) 2022-04-28

Similar Documents

Publication Publication Date Title
Kamakura et al. Long-term prognosis of probands with Brugada-pattern ST-elevation in leads V1–V3
Wallmann et al. Frequent atrial premature beats predict paroxysmal atrial fibrillation in stroke patients: an opportunity for a new diagnostic strategy
Pokorná et al. A sudden increase in partial pressure end-tidal carbon dioxide (PETCO2) at the moment of return of spontaneous circulation
Dekker et al. Low heart rate variability in a 2-minute rhythm strip predicts risk of coronary heart disease and mortality from several causes: the ARIC Study
Oehler et al. QRS‐T angle: a review
Bär et al. Acute psychosis leads to increased QT variability in patients suffering from schizophrenia
Magnani et al. Electrocardiographic PR interval and adverse outcomes in older adults: the Health, Aging, and Body Composition study
Sadoul et al. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy
Tereshchenko et al. Predictive value of beat-to-beat QT variability index across the continuum of left ventricular dysfunction: competing risks of noncardiac or cardiovascular death and sudden or nonsudden cardiac death
Kral et al. Exaggerated reactivity to mental stress is associated with exercise-induced myocardial ischemia in an asymptomatic high-risk population
Piccirillo et al. Autonomic modulation and QT interval dispersion in hypertensive subjects with anxiety
van der Ende et al. Population‐based values and abnormalities of the electrocardiogram in the general Dutch population: the lifelines cohort study
Romero et al. Depolarization changes during acute myocardial ischemia by evaluation of QRS slopes: standard lead and vectorial approach
Dehghani et al. A rapid decline in corneal small fibers and occurrence of foot ulceration and Charcot foot
Albarado-Ibañez et al. The role of the autonomic nervous system on cardiac rhythm during the evolution of diabetes mellitus using heart rate variability as a biomarker
Erdoğan et al. Relationship of fragmented QRS with prognostic markers and in-hospital MACE in patients undergoing CABG
MX2023004515A (es) Metodos para evaluar el riesgo de desarrollar una enfermedad.
Jaryal et al. Monitoring of cardiovascular reactivity to cold stress using digital volume pulse characteristics in health and diabetes
Dawood et al. Electrocardiographic spatial QRS-T angle and incident cardiovascular disease in HIV-infected patients (from the Strategies for the Management of Antiretroviral Therapy [SMART] study)
Xu et al. Hidden fatal ECG manifestations
Muramoto et al. Spectrum of ST amplitude: Athletes and an ambulatory clinical population
Fleischmann et al. The new universal definition of myocardial infarction criteria improve electrocardiographic diagnosis of acute coronary syndrome
Conde et al. Algorithm for probable acute coronary syndrome using high-sensitivity troponin T assay vs fourth-generation troponin T assay
Beckers et al. Association between restoration of autonomic modulation in the native sinus node and hemodynamic improvement after cardiac transplantation1
Palmieri et al. Weighted time warping improves T-wave morphology markers clinical significance